Transitioning from Remodulin (treprostinil) to Uptravi (selexipag) is a significant change in your treatment plan for pulmonary hypertension. Here are some key points from the knowledge base:
Remodulin (Treprostinil)
- Administration: Continuous infusion, either subcutaneously or intravenously
- Common Side Effects: Skin Show Full Answer
Transitioning from Remodulin (treprostinil) to Uptravi (selexipag) is a significant change in your treatment plan for pulmonary hypertension. Here are some key points from the knowledge base:
Remodulin (Treprostinil)
- Administration: Continuous infusion, either subcutaneously or intravenously.
- Common Side Effects: Skin reactions at infusion sites, headache, jaw pain, nausea, diarrhea, edema, and hypotension.
- Risks: Intravenous infusion carries a risk of serious infection, including life-threatening sepsis.
Uptravi (Selexipag)
- Purpose: Delays disease progression and reduces the risk of hospitalization in cases of pulmonary arterial hypertension (PAH).
- Mechanism: Prostacyclin receptor agonist, mimicking the effect of prostaglandins to dilate blood vessels and slow scarring in the lungs.
Transition Considerations
- Monitoring: Close monitoring by your healthcare provider is essential during the transition to manage any side effects or complications.
- Support: Connecting with others who have undergone similar transitions can provide valuable support and insights.
For more detailed information, you can visit the respective pages on Remodulin and Uptravi:
- [Remodulin](https://www.myPHteam.com/treatments/remodulin)
- [Uptravi](https://www.myPHteam.com/treatments/uptravi)
If you have specific concerns or experiences to share, discussing them with your healthcare provider or a support group can be very helpful.
July 25, 2024
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
